Preclinical data shows Antisoma's AS1411 reduces tumor growth in renal, lung cancer

By E. Janene Geiss

Philadelphia, April 4 - Antisoma plc said Tuesday that new data on its aptamer drug AS1411 showed it clearly reduced tumor growth in xenograft models of both renal and lung cancers.

The effects were statistically significant and seen at doses comparable to those used in clinical trial patients, according to a company news release.

These findings support Antisoma's strategy of enrolling additional patients with renal and lung cancers into an extended phase 1 trial. The positive findings in renal xenografts also are consistent with earlier data from the phase 1 trial, which reported promising signs of anticancer activity among three patients with renal cancer, officials said.

Antisoma said it expects the further clinical development of AS1411 to have two parallel elements: an expedited program in renal cancer and a more conventional program in a number of other cancers.

Data was presented Tuesday at the American Association of Cancer Research, highlighting the range of malignancies in which AS1411 has potential.

The latest experiments on isolated cancer cells show effective killing of prostate as well as lung cancer cells, in addition to cells from a variety of blood cancer lines like myelomas and lymphomas.

"The positive preclinical data presented at AACR provide strong support for AS1411 in the indications currently under clinical study and endorse the view that the drug's potential extends to a considerable variety of other blood and solid cancers," Antisoma chief executive officer Glyn Edwards said in the release.

Antisoma is a London biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognized academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.